CYCCP News and Press, Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock From 08/09/23

- Key Catalysts ahead with Multiple Value Generating Readouts- - Expects to Release Phase 1/2 Data with Oral Fadraciclib - - Signals of Single-agent Efficacy with Oral Plogosertib - - Management to Host Conference Call at 4:30 pm EDT Today- BERKELEY HEIGH...

BERKELEY HEIGHTS, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2023 financial results on Wed...

2023-05-11 19:59:08 ET Cyclacel Pharmaceuticals Inc. (CYCC) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - CEO Mark Kirschbaum - CMO Paul McBarron - CFO Conference Call Participants Ahu...

- Key Catalysts ahead with multiple Value Generating Readouts - - Expects to Report Phase 1/2 Data Releases with Oral Fadraciclib - - Advancing single-agent Efficacy with Differentiated Oral Plogosertib - - Adds to Balance Sheet with non-dilutive $4.7 million fro...

BERKELEY HEIGHTS, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2023 financial results on Thurs...

BERKELEY HEIGHTS, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it received a payment of £3.9 million (...

BERKELEY HEIGHTS, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that the Company plans to participate in ...

2023-03-06 21:04:08 ET Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2022 Earnings Conference Call March 6, 2023 16:30 ET Company Participants Irina Koffler - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice Pres...

- On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2023 and Report Interim data in 2H 2023 - - Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation - - Expect to Report Initial Data from Oral Plogosertib 140-101 Do...

BERKELEY HEIGHTS, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2022 financial ...